VEGFA and metastatic colorectal cancer: Bevacizumab, a humanized variant of a VEGF neutralizing monoclonal antibody (150), was approved by the FDA (Food & Drug Administration) in 2003 as a first anti-angiogenic factor as a supplement to therapy with standard of care (SOC) in patients with metastatic colorectal cancer (151).